TMX-049 - A Phase 1, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects
Latest Information Update: 04 Jun 2018
At a glance
- Drugs TMX 049 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors Teijin Pharma
- 30 May 2018 Status changed from recruiting to completed.
- 14 Dec 2016 New trial record